Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Jeff Donovan, MD, PhD, FRCPC JAAD Case Reports

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients Patrizia Weber, MD, S. Morteza Seyed Jafari,

A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: A randomized, physician-blinded,

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis is associated with lipid abnormalities at the onset of skin disease Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Combined acitretin and Candida antigen versus either agent alone in the treatment of recalcitrant warts Ahmad Nofal, MD, Fathia Khattab, MD, Eman Nofal,

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

308-nm excimer laser therapy in alopecia areata

Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary.

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Fever, eosinophilia, and a rash

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Infectious rash after riding elephants

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Which Treatment Is Better

Hugh Gloster, MD, Chesahna Kindred, MBA

Medicaid acceptance among pediatric dermatologists

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Penile calciphylaxis Journal of the American Academy of Dermatology

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Gordon W. Jung, MD, Patricia T. Ting, MSc, MD, Thomas G

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault, MSc, Robert Bissonnette, MD, FRCPC Journal of the American Academy of Dermatology Volume 70, Issue 6, Pages 1139-1141 (June 2014) DOI: 10.1016/j.jaad.2013.12.006 Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Patient disposition. Journal of the American Academy of Dermatology 2014 70, 1139-1141DOI: (10.1016/j.jaad.2013.12.006) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Notalgia paresthetica. Progression of pruritus (A) and area of hyperpigmentation (B) over time for patients randomized to botulinum toxin A (BTX-A; black diamonds) and placebo (gray squares). Patients initially randomized to placebo received BTX-A at week 12. Number of subjects with hyperpigmentation at baseline were 6 and 7 for placebo and BTX-A, respectively. The imputation method used for pruritus and hyperpigmentation was last observation carried forward. Journal of the American Academy of Dermatology 2014 70, 1139-1141DOI: (10.1016/j.jaad.2013.12.006) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions